Terms: = Prostate cancer AND CREBBP, CBP, 1387, ENSG00000005339, RSTS, RTS
153 results:
1. EP300/crebbp acetyltransferase inhibition limits steroid receptor and FOXA1 signaling in prostate cancer cells.
Huttunen J; Aaltonen N; Helminen L; Rilla K; Paakinaho V
Cell Mol Life Sci; 2024 Apr; 81(1):160. PubMed ID: 38564048
[TBL] [Abstract] [Full Text] [Related]
2. Discovery of cbpD-409 as a Highly Potent, Selective, and Orally Efficacious cbp/p300 PROTAC Degrader for the Treatment of Advanced prostate cancer.
Chen Z; Wang M; Wu D; Zhao L; Metwally H; Jiang W; Wang Y; Bai L; McEachern D; Luo J; Wang M; Li Q; Matvekas A; Wen B; Sun D; Chinnaiyan AM; Wang S
J Med Chem; 2024 Apr; 67(7):5351-5372. PubMed ID: 38530938
[TBL] [Abstract] [Full Text] [Related]
3. cbp/p300 Degrader: A Promising Therapeutic Strategy for Treatment of prostate cancer and Beyond.
Hu J; Xu Y
J Med Chem; 2024 Apr; 67(7):5272-5274. PubMed ID: 38517344
[TBL] [Abstract] [Full Text] [Related]
4. Aberrant DNA methylation distorts developmental trajectories in atypical teratoid/rhabdoid tumors.
Pekkarinen M; Nordfors K; Uusi-Mäkelä J; Kytölä V; Hartewig A; Huhtala L; Rauhala M; Urhonen H; Häyrynen S; Afyounian E; Yli-Harja O; Zhang W; Helen P; Lohi O; Haapasalo H; Haapasalo J; Nykter M; Kesseli J; Rautajoki KJ
Life Sci Alliance; 2024 Jun; 7(6):. PubMed ID: 38499326
[TBL] [Abstract] [Full Text] [Related]
5. Discovery of cbpD-268 as an Exceptionally Potent and Orally Efficacious cbp/p300 PROTAC Degrader Capable of Achieving Tumor Regression.
Chen Z; Wang M; Wu D; Bai L; Xu T; Metwally H; Wang Y; McEachern D; Zhao L; Li R; Takyi-Williams J; Wang M; Wang L; Li Q; Wen B; Sun D; Wang S
J Med Chem; 2024 Apr; 67(7):5275-5304. PubMed ID: 38477974
[TBL] [Abstract] [Full Text] [Related]
6. Single-cell deconvolution algorithms analysis unveils autocrine IL11-mediated resistance to docetaxel in prostate cancer via activation of the JAK1/STAT4 pathway.
Cheng B; Li L; Luo T; Wang Q; Luo Y; Bai S; Li K; Lai Y; Huang H
J Exp Clin Cancer Res; 2024 Mar; 43(1):67. PubMed ID: 38429845
[TBL] [Abstract] [Full Text] [Related]
7. Androgen receptor cofactors: A potential role in understanding prostate cancer.
Li X; Xiong H; Mou X; Huang C; Thomas ER; Yu W; Jiang Y; Chen Y
Biomed Pharmacother; 2024 Apr; 173():116338. PubMed ID: 38417290
[TBL] [Abstract] [Full Text] [Related]
8. Exploiting epigenetic targets to overcome taxane resistance in prostate cancer.
Cevatemre B; Bulut I; Dedeoglu B; Isiklar A; Syed H; Bayram OY; Bagci-Onder T; Acilan C
Cell Death Dis; 2024 Feb; 15(2):132. PubMed ID: 38346967
[TBL] [Abstract] [Full Text] [Related]
9. Androgen Receptor-Interacting Proteins in prostate cancer Development and Therapy Resistance.
Culig Z; Puhr M
Am J Pathol; 2024 Mar; 194(3):324-334. PubMed ID: 38104650
[TBL] [Abstract] [Full Text] [Related]
10. Linking African ancestral substructure to prostate cancer health disparities.
Gheybi K; Mmekwa N; Lebelo MT; Patrick SM; Campbell R; Nenzhelele M; Soh PXY; Obida M; Loda M; Shirindi J; Butler EN; Mutambirwa SBA; Bornman MSR; Hayes VM
Sci Rep; 2023 Nov; 13(1):20909. PubMed ID: 38017150
[TBL] [Abstract] [Full Text] [Related]
11. Automation, live-cell imaging, and endpoint cell viability for prostate cancer drug screens.
Lyles RDZ; Martinez MJ; Sherman B; Schürer S; Burnstein KL
PLoS One; 2023; 18(10):e0287126. PubMed ID: 37815978
[TBL] [Abstract] [Full Text] [Related]
12. Reevaluation of bromodomain ligands targeting BAZ2A.
Cazzanelli G; Vedove AD; Parolin E; D'Agostino VG; Unzue A; Nevado C; Caflisch A; Lolli G
Protein Sci; 2023 Sep; 32(9):e4752. PubMed ID: 37574751
[TBL] [Abstract] [Full Text] [Related]
13. Androgen Receptor Variants Confer Castration Resistance in prostate cancer by Counteracting Antiandrogen-Induced Ferroptosis.
Sun R; Yan B; Li H; Ding D; Wang L; Pang J; Ye D; Huang H
Cancer Res; 2023 Oct; 83(19):3192-3204. PubMed ID: 37527336
[TBL] [Abstract] [Full Text] [Related]
14. Development of a multiplex assay to assess activated p300/cbp in circulating prostate tumor cells.
Filon M; Yang B; Purohit TA; Schehr J; Singh A; Bigarella M; Lewis P; Denu J; Lang J; Jarrard DF
Oncotarget; 2023 Jul; 14():738-746. PubMed ID: 37477521
[TBL] [Abstract] [Full Text] [Related]
15. Overexpression of miR-17-5p may negatively impact p300/cbp factor-associated inflammation in a hypercholesterolemic advanced prostate cancer model.
Pimenta R; Camargo JA; Gonçalves GL; Ghazarian V; Candido P; Guimarães VR; Romão P; Chiovatto C; da Silva KS; Dos Santos GA; Silva IA; Nahas WC; Leite KR; Pessoa AFM; Viana NI; Reis ST
Mol Biol Rep; 2023 Sep; 50(9):7333-7345. PubMed ID: 37439896
[TBL] [Abstract] [Full Text] [Related]
16. FT-6876, a Potent and Selective Inhibitor of cbp/p300, is Active in Preclinical Models of Androgen Receptor-Positive Breast cancer.
Caligiuri M; Williams GL; Castro J; Battalagine L; Wilker E; Yao L; Schiller S; Toms A; Li P; Pardo E; Graves B; Azofeifa J; Chicas A; Herbertz T; Lai M; Basken J; Wood KW; Xu Q; Guichard SM
Target Oncol; 2023 Mar; 18(2):269-285. PubMed ID: 36826464
[TBL] [Abstract] [Full Text] [Related]
17. Cholesterol Triggers Nuclear Co-Association of Androgen Receptor, p160 Steroid Coactivators, and p300/cbp-Associated Factor Leading to Androgenic Axis Transactivation in Castration-Resistant prostate cancer.
Pimenta R; Camargo JA; Candido P; Ghazarian V; Gonçalves GL; Guimarães VR; Romão P; Chiovatto C; Mioshi CM; Dos Santos GA; Silva IA; Birbrair A; Srougi M; Nahas WC; Leite KR; Viana NI; Reis ST
Cell Physiol Biochem; 2022 Dec; 56(S4):1-15. PubMed ID: 36458578
[TBL] [Abstract] [Full Text] [Related]
18. Lysine Acetyltransferases and Their Role in AR Signaling and prostate cancer.
Jaiswal B; Agarwal A; Gupta A
Front Endocrinol (Lausanne); 2022; 13():886594. PubMed ID: 36060957
[TBL] [Abstract] [Full Text] [Related]
19. New approaches to targeting epigenetic regulation in prostate cancer.
Thompson D; Choo N; Bolton DM; Lawrentschuk N; Risbridger GP; Lawrence MG; Taylor RA
Curr Opin Urol; 2022 Sep; 32(5):472-480. PubMed ID: 35869742
[TBL] [Abstract] [Full Text] [Related]
20. Acetylated HOXB13 Regulated Super Enhancer Genes Define Therapeutic Vulnerabilities of Castration-Resistant prostate cancer.
Nguyen DT; Yang W; Renganathan A; Weimholt C; Angappulige DH; Nguyen T; Sprung RW; Andriole GL; Kim EH; Mahajan NP; Mahajan K
Clin Cancer Res; 2022 Sep; 28(18):4131-4145. PubMed ID: 35849143
[TBL] [Abstract] [Full Text] [Related]
[Next]
